Imvotamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic activity. Imvotamab contains ten high affinity binding domains for the tumor-associated antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon administration, imvotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Additionally, imvotamab induces complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3 IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor cells. The extra binding units of imvotamab may bind cancer cells that express relatively low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies, imvotamab appears to induce less cytokine release, which may reduce the risk of cytokine release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.

**Synonyms:** - Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323 - Bispecific CD20xCD3 IgM Antibody IGM2323 - Bispecific IgM Antibody IGM2323 - IGM 2323 - IGM-2323 - IGM2323 - IMVOTAMAB - IgM Pentamer IGM2323